Fish oil intake and seizure control in children with medically resistant epilepsy

Reda, Diala Mohamed Ali; El-Fatah, Nesrin K. Abd; Omar, Tarek; Darwish, Olfat Abdel Hamid

doi:10.4103/1947-2714.161248

Cited by 27 publications

(20 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on the low level of omega-3 fatty acids, she was also started on Lovaza (ethyl-EPA/ethyl-DHA) at a dose of 1860/1500 mg daily (total EPA + DHA: 3,360 mg/d). Consistent with recent evidence that fish oil supplementation elevates seizure thresholds and reduces seizure frequency in epileptic patients [ 184 , 185 ], at six-month follow-up she had been seizure-free, was able to live independently and reported no self-injurious behaviors.…”

Section: Clinical Vignettessupporting

confidence: 83%

Detection and treatment of omega-3 fatty acid deficiency in psychiatric practice: Rationale and implementation

Messamore

McNamara

2016

Lipids Health Dis

View full text Add to dashboard Cite

A body of translational evidence has implicated dietary deficiency in long-chain omega-3 (LCn-3) fatty acids, including eicosapenaenoic acid (EPA) and docosahexaenoic acid (DHA), in the pathophysiology and potentially etiology of different psychiatric disorders. Case–control studies have consistently observed low erythrocyte (red blood cell) EPA and/or DHA levels in patients with major depressive disorder, bipolar disorder, schizophrenia, and attention deficit hyperactivity disorder. Low erythrocyte EPA + DHA biostatus can be treated with fish oil-based formulations containing preformed EPA + DHA, and extant evidence suggests that fish oil supplementation is safe and well-tolerated and may have therapeutic benefits. These and other data provide a rationale for screening for and treating LCn-3 fatty acid deficiency in patients with psychiatric illness. To this end, we have implemented a pilot program that routinely measures blood fatty acid levels in psychiatric patients entering a residential inpatient clinic. To date over 130 blood samples, primarily from patients with treatment-refractory mood or anxiety disorders, have been collected and analyzed. Our initial results indicate that the majority (75 %) of patients exhibit whole blood EPA + DHA levels at ≤4 percent of total fatty acid composition, a rate that is significantly higher than general population norms (25 %). In a sub-set of cases, corrective treatment with fish oil-based products has resulted in improvements in psychiatric symptoms without notable side effects. In view of the urgent need for improvements in conventional treatment algorithms, these preliminary findings provide important support for expanding this approach in routine psychiatric practice.

show abstract

Section: Clinical Vignettessupporting

confidence: 83%

Detection and treatment of omega-3 fatty acid deficiency in psychiatric practice: Rationale and implementation

Messamore

McNamara

2016

Lipids Health Dis

View full text Add to dashboard Cite

show abstract

“…In one study, fish oil was used for intervention group (240 mg DHA and 360 mg EPA plus Vitamin E) and corn oil for control group. [ 34 ]…”

Section: Resultsmentioning

confidence: 99%

Association of Omega-3 fatty acid and epileptic seizure in epileptic patients: A systematic review

Pourmasoumi

Vosoughi

Derakhshandeh-Rishehri

et al. 2018

Int J Prev Med

View full text Add to dashboard Cite

The evidence on the association between omega-3 consumption and epileptic seizure is inconsistent. Therefore, we have conducted this systematic review to clarify the possible relationship. Original articles were searched in electronic databases (PubMed, Scopus, Google Scholar, Cochrane, and Ovid) and by reviewing the reference lists of retrieved articles. The main evaluated outcome was the epileptic seizures. We included the English language studies that reported the original data on the effect of omega-3 on epileptic human patients. We included the nine articles with 230 patients in the present systematic review. The mean ± standard deviation age of them was about 31.01 ± 14.99 years. The average of study duration was 22 ± 15.27 weeks. Omega-3 fatty acid supplements were defined as the sum of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) (1100 mg/d); as the sum of EPA, DHA, and alpha-linolenic acid (5 g/d); and as the sum of EPA alone (565 mg/d) in different studies. Among the nine studies, four studies reported a significant positive association between omega-3 fatty acids and epileptic seizures. However, power and quality of these studies are low, and we cannot consider the beneficial effect of omega-3 on seizures. In addition, five studies did not reveal any significant effect. Majority of the included studies did not show a significant association between omega-3 and epileptic seizure in epileptic patients, but further studies are necessary. It is controversial whether omega-3 fatty acids can produce positive effects on epileptic patients or not.

show abstract

“…Mouse models show inflammatory pathways involved in allergic diseases that may also be activated in the brain and may cause epilepsy ( 36 ). Dietary supplementation with either ω3 fatty acids or medium chain triglycerides are used to improve seizure control in individuals with refractory epilepsy ( 37 – 41 ) and are also successfully administered to dogs with atopic dermatitis ( 42 , 43 ). Thus, there may be a link between allergic diseases and epilepsy leading to cutaneous signs in epileptic dogs independent of antiepileptic therapy.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous Adverse Drug Reactions in Dogs Treated with Antiepileptic Drugs

et al. 2016

View full text Add to dashboard Cite

Epilepsy is one of the most common neurologic disorders in dogs and life-long treatment with antiepileptic drugs (AED) is frequently required. Adverse events of AED targeting the skin are only rarely reported in veterinary medicine and the true incidence and spectrum of cutaneous reactions in epileptic dogs remains unknown. In this study, we hypothesized that cutaneous reactions commonly occur in epileptic dogs and are related to AED treatment. A retrospective case review of 185 dogs treated for epilepsy identified 20.0% with simultaneous appearance of dermatologic signs. In a subsequent prospective case investigation (n = 137), we identified newly appearing or distinct worsening of skin lesions following initiation of AED therapy in 10.9% of dogs treated for epilepsy (95% CI 6.8–17.7%). Cutaneous lesions were classified as probably drug-induced in 40.0% of these cases. Patch testing and intradermal testing were further investigated as potential diagnostic methods to confirm AED hypersensitivity. They were of high specificity but sensitivity and positive predictive value appeared inappropriate to recommend their routine use in clinical practice.

show abstract

Fish oil intake and seizure control in children with medically resistant epilepsy

Cited by 27 publications

References 14 publications

Detection and treatment of omega-3 fatty acid deficiency in psychiatric practice: Rationale and implementation

Detection and treatment of omega-3 fatty acid deficiency in psychiatric practice: Rationale and implementation

Association of Omega-3 fatty acid and epileptic seizure in epileptic patients: A systematic review

Cutaneous Adverse Drug Reactions in Dogs Treated with Antiepileptic Drugs

Contact Info

Product

Resources

About